These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 30923630)

  • 41. Metreleptin treatment for congenital generalized lipodystrophy type 4 (CGL4): a case report.
    Takeyari S; Takakuwa S; Miyata K; Yamamoto K; Nakayama H; Ohata Y; Fujiwara M; Kitaoka T; Kubota T; Namba N; Sakai N; Ozono K
    Clin Pediatr Endocrinol; 2019; 28(1):1-7. PubMed ID: 30745727
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Metabolomic Analysis of the Effects of Leptin Replacement Therapy in Patients with Lipodystrophy.
    Grewal S; Gubbi S; Fosam A; Sedmak C; Sikder S; Talluru H; Brown RJ; Muniyappa R
    J Endocr Soc; 2020 Jan; 4(1):bvz022. PubMed ID: 32010873
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and Safety of Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded Access Program.
    Ajluni N; Dar M; Xu J; Neidert AH; Oral EA
    J Diabetes Metab; 2016 Mar; 7(3):. PubMed ID: 27642538
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Metreleptin Effectiveness and Safety Registry (MEASuRE): concept, design and challenges.
    Haymond MW; Araújo-Vilar D; Balser J; Lewis JH; Louzado R; Musso C; von Schnurbein J; Wabitsch M;
    Orphanet J Rare Dis; 2023 May; 18(1):127. PubMed ID: 37237416
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Case Report of Acquired Generalized Lipodystrophy Associated With Common Variable Immunodeficiency.
    Halpern B; Nery M; Pereira MAA
    J Clin Endocrinol Metab; 2018 Aug; 103(8):2807-2810. PubMed ID: 29846625
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of Metreleptin Treatment in Familial Partial Lipodystrophy Due to PPARG vs LMNA Pathogenic Variants.
    Sekizkardes H; Cochran E; Malandrino N; Garg A; Brown RJ
    J Clin Endocrinol Metab; 2019 Aug; 104(8):3068-3076. PubMed ID: 31194872
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A case of acquired generalized lipodystrophy with cerebellar degeneration and type 2 diabetes mellitus.
    Chao PJ; Tsai JC; Chang DM; Shin SJ; Lee YJ
    Rev Diabet Stud; 2004; 1(4):193-7. PubMed ID: 17491704
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Metreleptin treatment of non-HIV lipodystrophy syndromes.
    Chevalier B; Lemaitre M; Leguier L; Mapihan KL; Douillard C; Jannin A; Espiard S; Vantyghem MC
    Presse Med; 2021 Nov; 50(3):104070. PubMed ID: 34571177
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Autoantibodies Against Perilipin 1 as a Cause of Acquired Generalized Lipodystrophy.
    Corvillo F; Aparicio V; López-Lera A; Garrido S; Araújo-Vilar D; de Miguel MP; López-Trascasa M
    Front Immunol; 2018; 9():2142. PubMed ID: 30283460
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Thyroid Abnormalities in Patients With Extreme Insulin Resistance Syndromes.
    Kushchayeva YS; Kushchayev SV; Startzell M; Cochran E; Auh S; Dai Y; Lightbourne M; Skarulis M; Brown RJ
    J Clin Endocrinol Metab; 2019 Jun; 104(6):2216-2228. PubMed ID: 30657911
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serum adiponectin and leptin levels in patients with lipodystrophies.
    Haque WA; Shimomura I; Matsuzawa Y; Garg A
    J Clin Endocrinol Metab; 2002 May; 87(5):2395. PubMed ID: 11994394
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A YOUNG ADULT WITH GENERALIZED LIPODYSTROPHY AND DIABETES MELLITUS (CASE REPORT).
    Çelo E; Kalari B; Toti F
    Georgian Med News; 2018 Apr; (277):27-31. PubMed ID: 29745909
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Marked Hypoleptinemia Precedes Overt Fat Loss in Immune Checkpoint Inhibitor-induced Acquired Generalized Lipodystrophy.
    Dhanasekaran M; Sandooja R; Higgins AS; Simha V
    JCEM Case Rep; 2023 Mar; 1(2):luad025. PubMed ID: 37908472
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy.
    Ebihara K; Kusakabe T; Hirata M; Masuzaki H; Miyanaga F; Kobayashi N; Tanaka T; Chusho H; Miyazawa T; Hayashi T; Hosoda K; Ogawa Y; DePaoli AM; Fukushima M; Nakao K
    J Clin Endocrinol Metab; 2007 Feb; 92(2):532-41. PubMed ID: 17118991
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An unusual case of acquired generalized lipodystrophy (panniculitis variety).
    Hill M; Weissman AS; Hirshburg J; McBride JD; Lawrence H
    Pediatr Dermatol; 2024; 41(6):1152-1155. PubMed ID: 38887123
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Durable remission in a patient with refractory subcutaneous panniculitis-like T-cell lymphoma relapse after allogeneic hematopoietic stem cell transplantation through withdrawal of cyclosporine.
    Yuan L; Sun L; Bo J; Zhou Y; Li HH; Yu L; Gao CJ
    Ann Transplant; 2011; 16(3):135-8. PubMed ID: 21959522
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A CASE OF ACQUIRED GENERALIZED LIPODYSTROPHY ASSOCIATED WITH PEMBROLIZUMAB IN A PATIENT WITH METASTATIC MALIGNANT MELANOMA.
    Bedrose S; Turin CG; Lavis VR; Kim ST; Thosani SN
    AACE Clin Case Rep; 2020; 6(1):e40-e45. PubMed ID: 32524008
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of Metreleptin in Patients with Generalized Lipodystrophy Before vs After the Onset of Severe Metabolic Disease.
    Brush M; Auh S; Cochran E; Tuska R; Koh C; Kleiner DE; Lightbourne M; Brown RJ
    J Clin Endocrinol Metab; 2024 May; ():. PubMed ID: 38757950
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Chidamide induces long-term remission in rare subcutaneous panniculitis-like T-cell lymphoma: An unusual case report and literature review.
    Li L; Wu C; Chai Y; Dong C; Zhao L
    Int J Immunopathol Pharmacol; 2021; 35():20587384211009342. PubMed ID: 33845613
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recombinant human leptin treatment in genetic lipodystrophic syndromes: the long-term Spanish experience.
    Araujo-Vilar D; Sánchez-Iglesias S; Guillín-Amarelle C; Castro A; Lage M; Pazos M; Rial JM; Blasco J; Guillén-Navarro E; Domingo-Jiménez R; del Campo MR; González-Méndez B; Casanueva FF
    Endocrine; 2015 May; 49(1):139-47. PubMed ID: 25367549
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.